What Makes TrialChoices One of the Largest Patient Recruitment Firms in Europe?
TrialChoices is one of the largest patient recruitment firms in Europe, giving research teams direct access to 5 million UK patients through its network of GP practices, with a further 9 million reachable through wider Primary Care Network (PCN) searches. But scale on its own is not what sets the model apart. It is the combination of size, live NHS records and a direct route to the GP that allows initial patient cohorts to be identified in hours and days rather than weeks and months.
This article explains what that scale looks like in practice, why it matters for modern clinical trials, and how TrialChoices is building on its UK foundations.
5 Million Patients Directly, 9 Million More On Demand
TrialChoices works with hundreds of GPs who collectively care for 5 million UK patients. These practices have signed up to the network directly, which means a study opportunity can be presented to them quickly and each practice can choose to opt in.
Beyond that, a wider PCN search can reach a further 9 million patients. PCN searches must meet specific criteria and are carried out on a pre-planned basis, which gives sponsors a second layer of reach for studies that need it, such as rare disease or highly targeted oncology trials.
The network has grown to the point where TrialChoices plans to close GP sign-up soon: 5 million patients is enough for now. The focus has shifted from building the network to putting it to work for researchers.
Why Size Matters In Patient Recruitment
When researchers hear about patient numbers, it is easy to think only about volume. In reality, scale matters most when criteria are narrow.
Every inclusion and exclusion criterion shrinks the pool. A study might need patients with a confirmed diagnosis, a specific disease stage, a particular treatment history and a defined age range, all within reach of a study site. Apply those filters to a small population and very few people remain. Apply them to millions of patients and there is still a meaningful cohort to work with.
That is the practical value of size. It allows highly specific studies to recruit without stretching timelines. TrialChoices has already shown what this looks like:
In a live study, 42 rare disease patients (US classification) were identified in just four hours.
The network can find 12 stage 4 cancer patients in a single geographical area within a few hours, with full access to medical history through the patient's GP.
For more on this, see our articles on why volume and reach matter most in rare disease recruitment and how real-time GP access changes oncology recruitment timelines.
Live Records, Not Static Databases
Many traditional recruitment models rely on third parties and static patient databases. The problem is that stored patient data outside the NHS starts going out of date the moment it leaves. A third-party record may not show a recent diagnosis, a change in medication, or even whether the patient is still alive.
TrialChoices takes a different approach. Rather than holding patient data, it works with GP practices whose own live records are reviewed against confirmed study criteria. That means:
Cohort estimates are based on patients as they are today.
Full medical history is available to the healthcare professionals reviewing it.
Feasibility planning is built on real numbers rather than projections.
Fewer patients fall out of the funnel because of outdated information.
Going Direct To The GP
Almost every clinical trial participant in the UK has the same key point of contact: their GP. Most UK clinical research starts and ends there, so TrialChoices asks a simple question: why not go direct?
The GP process is straightforward. TrialChoices finds research opportunities from approved organisations and lets its GP partners know what is being planned in advance. Each practice opts in or out. Once selection criteria and logistics are confirmed, the practice team reviews its own patient data for suitable participants, and TrialChoices puts them in touch with the research team.
Going direct removes the delays, bad data, bureaucracy and unnecessary admin layers that slow many studies down. It also means patients hear about research from a clinician they already trust, which supports informed decisions and stronger engagement. Many TrialChoices GP partners are already established research hubs, so they understand what a well-run study needs.
Patient Data Stays Within The NHS
Scale is only valuable if it is handled responsibly. Under the TrialChoices model, personal data stays securely within the NHS. TrialChoices does not need access to patient records; the information remains within the GP practice or is handled securely by the relevant research organisation, and practices only review their data once a study is confirmed and active.
TrialChoices also carries out extensive, detailed screening of every research partner and shares that information with GP practices during recruitment. Every trial brought to GPs is registered with the appropriate agencies. This patients-and-NHS-first approach is central to how the company works.
A Model That Keeps Value In Primary Care
Access to NHS patient data is estimated to be worth around £6 billion a year, yet GP practices rarely see much of that value. TrialChoices changes that. It negotiates the recruitment fee on behalf of its GPs and commits to passing 100% of the best commercial recruitment fee directly to the practice.
This matters for researchers too. When GP practices are properly rewarded for research, they are more willing to take part, which keeps the network engaged and growing. It is one of the reasons TrialChoices has been able to build a network of this size.
Why Faster UK Recruitment Matters Now
The UK has made real progress on trial set-up. The government reported in April 2026 that the average set-up time for a commercial interventional trial had fallen from 169 days to 122 days, and regulatory reviews now typically complete within 60 days.
Recruitment is where the challenge remains. According to the ABPI's annual clinical trials report, published in November 2026, just 17,618 people took part in industry clinical trials in the NHS in 2025/26, 31% fewer than in 2022/23. On average, only 35% of studies opened to recruitment within 60 days of approval, and 53% recruited their first patient within 30 days of opening.
At the same time, UK sites recruited 100 global or European first participants into commercial international studies in 2025/26, almost double the previous year. The UK can lead Europe in getting new treatments to patients first, but only if eligible participants can be found quickly. That is exactly the gap TrialChoices was set up to close, with the aim of reducing study start-up from months and years to weeks.
Building On UK Foundations
TrialChoices was built in the UK, where the NHS and GP-registered population create a unique opportunity for direct, real-time patient identification. The same GP-led model is now expanding.
TrialChoices has opened applications for German GPs (Hausärzte) to join its new German network, and is also welcoming personal physicians in the USA. The goal is the same in every market: connect patients with global research through the doctors who already know them best.
Who TrialChoices Works With
TrialChoices supports organisations across the research landscape, including:
Pharmaceutical and biotech sponsors.
Contract research organisations (CROs).
MedTech, AI and medical device companies.
Academic and university research teams.
Charities and patient advocacy groups.
Primary care, secondary care and consultants.
Whether you are running a commercial Phase III study, an academic trial working to a tight budget, or a charity-backed study into a rare or underserved condition, the principle is the same: find the right patients, in the right place, at the right time.
Frequently Asked Questions
Is TrialChoices one of the largest patient recruitment firms in Europe?
Yes. TrialChoices has direct access to 5 million UK patients through its GP network, with a further 9 million reachable through wider PCN searches, making it one of the largest patient recruitment firms in Europe.
How many patients can TrialChoices reach?
TrialChoices has direct access to 5 million patients through its GP partners and indirect access to a further 9 million via wider Primary Care Network searches, which are carried out on a pre-planned basis.
How quickly can TrialChoices identify patients?
Because GP practices review live records against confirmed study criteria, initial cohorts can be identified in hours and days. In one live study, 42 rare disease patients were identified in four hours.
Does TrialChoices hold patient data?
No. Personal data stays securely within the NHS. Patient information remains within the GP practice or is handled securely by the relevant research organisation.
Which countries does TrialChoices work in?
TrialChoices is built on its UK GP network and is expanding, with a new German network now open to applications from GPs and a sign-up route for personal physicians in the USA.
Final Thoughts
Being one of the largest patient recruitment firms in Europe is about more than headline numbers. For TrialChoices, scale means research teams can apply demanding criteria and still find suitable patients. Live records mean those numbers are accurate. And going direct to the GP means patients are approached by someone they trust, quickly and responsibly.
Contact TrialChoices
If your study needs fast access to eligible patients, TrialChoices can help. Share your protocol synopsis, key eligibility criteria and target geography, and we will show you what an initial cohort could look like across our network.
Call +44 (0)7711 248 610 or email info@trialchoices.org to find out how direct access to millions of patients can accelerate your next clinical trial. GP practices interested in joining can register here.
Comments